Functional Dyspepsia Market Size in the 7MM was USD 1,799.9 million in 2020

The Functional Dyspepsia market report provides current treatment practices, emerging drugs, Functional Dyspepsia market share of the individual therapies, current and forecasted Functional Dyspepsia market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Functional Dyspepsia treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Functional Dyspepsia market.

"The growth in the Functional Dyspepsia market is limited by the lack of universal diagnostic criteria and limited emerging treatment options"

Key takeaways from the Functional Dyspepsia Market Research Report

• The total number of prevalent cases of Functional Dyspepsia associated in 7MM countries was 48,959.8 in 2020.

• Functional Dyspepsia market size in the seven major markets was USD 1,799.9 million in 2020.

• Functional Dyspepsia Market Companies includes Astellas Pharma & Zeria Pharmaceuticals, Dong-A ST, and others.

• Functional Dyspepsia Pipeline Therapies includes UI05MSP015CT, Gasmotin, DWJ1252, Imonogas, Espumisan, Rabeprazole, Z-338, GW679769 oral tablets, YM443, and others.

To discover which therapies are expected to grab the major Functional Dyspepsia Market share, click here for Functional Dyspepsia Market Research Report @ https://www.delveinsight.com/sample-request/functional-dyspepsia-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Functional Dyspepsia Overview

Dyspepsia is a constellation of symptoms predominantly in the gastroduodenal region of the upper gastrointestinal tract. Functional dyspepsia is defined as at least 1 month of epigastric discomfort without evidence of organic disease found during an upper endoscopy, and it accounts for 70% of dyspepsia. The Rome diagnostic criteria classified Functional dyspepsia into two non-exclusive subtypes: postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS). The key symptoms of Functional dyspepsia are early satiety, postprandial fullness, epigastric pain, or burning. Other symptoms may include nausea, vomiting, loss of appetite. Though Functional dyspepsia is a prevalent functional gastrointestinal disorder (FGID), it is often difficult to diagnose as it is caused by heterogeneous factors. The major pathogenesis of Functional dyspepsia includes infectious and post-infectious changes in the gut, abnormal gastric motility, visceral hypersensitivity, and psychosocial and genetic factors.

Functional Dyspepsia Epidemiology Segmentation in the 7MM
• Functional Dyspepsia Prevalence
• Functional Dyspepsia Type-specific cases
• Functional Dyspepsia Age-specific Cases
• Functional Dyspepsia Gender-specific cases

Download the report to understand which factors are driving Functional Dyspepsia epidemiology trends, click here for Functional Dyspepsia epidemiology segmentation @ https://www.delveinsight.com/sample-request/functional-dyspepsia-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Functional Dyspepsia Emerging Drug

Motilitone (DA-9701): Dong-A ST

Motilitone (DA-9701) is a new herbal drug consisting of Corydalis Tuber and Pharbitidis Semen, which has been developed to treat functional dyspepsia. The heterogeneous symptom pattern and multiple causes of functional dyspepsia have resulted in numerous drug target strategies for its treatment. DA-9701, with its multiple mechanisms of action, such as fundus relaxation, visceral analgesia, and prokinetic effects, improves functional dyspepsia symptoms in affected patients. While its safety profile is preferable to other treatments, its pharmacological effects also include conventional effects, such as enhanced gastric emptying and gastrointestinal transit.

Currently, the molecule is in the developmental phase in the United States, and Phase II was completed in 2018.

Functional Dyspepsia Market Outlook
According to DelveInsight, the Functional Dyspepsia market in 7MM is expected to grow in the study period 2019-2032. Due to the diverse clinical manifestations of Functional dyspepsia, for a majority of patients, the treatment is symptom-based. Eradication therapy should be offered to patients with Functional dyspepsia who test positive for H. pylori. Other therapies with evidence of effectiveness include proton pump inhibitors, histamine-2 receptor antagonists, prokinetics, and central neuromodulators. Though psychological therapies are helpful in some cases, psychological therapies as a clinical guideline are uncertain.

To learn more about the Functional Dyspepsia FDA-approved drugs, click here for Functional Dyspepsia Emerging Drugs & Companies, Know about Functional Dyspepsia Treatment Market @ https://www.delveinsight.com/sample-request/functional-dyspepsia-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Functional Dyspepsia Market Report

• Coverage- 7MM

• Functional Dyspepsia Companies- tellas Pharma & Zeria Pharmaceuticals, Dong-A ST, and others.

• Functional Dyspepsia Pipeline Therapies- UI05MSP015CT, Gasmotin, DWJ1252, Imonogas, Espumisan, Rabeprazole, Z-338, GW679769 oral tablets, YM443, and others

• Functional Dyspepsia Market Dynamics: Functional Dyspepsia Market Barriers and Drivers

• Functional Dyspepsia Market Access and Reimbursement

To discover more about Functional Dyspepsia Market Drugs in development, click here for Functional Dyspepsia Market Dynamics and Functional Dyspepsia Market Drivers & Barriers @ https://www.delveinsight.com/sample-request/functional-dyspepsia-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content

1. Key Insights
2. Executive Summary of Functional Dyspepsia
3. Competitive Intelligence Analysis for Functional Dyspepsia
4. Functional Dyspepsia: Market Overview at a Glance
5. Functional Dyspepsia: Disease Background and Overview
6. Patient Journey
7. Functional Dyspepsia Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Functional Dyspepsia Unmet Needs
10. Key Endpoints of Functional Dyspepsia Treatment
11. Functional Dyspepsia Marketed Products
12. Functional Dyspepsia Emerging Therapies
13. Functional Dyspepsia: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Functional Dyspepsia
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

To read more about the Functional Dyspepsia Patient Population of the report, click here for Functional Dyspepsia Unmet Needs and Patient Journey @ https://www.delveinsight.com/sample-request/functional-dyspepsia-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

This release was published on openPR.